Grant: Fellowship - Priority Announcement: Gastroenterology
University of British Columbia
$45,000.00
The role of NPM1 in apoptosis resistance in colorectal cancer
FY 2013-14
Summary
Colorectal cancer (CRC) is a leading cause of cancer-related deaths in Canada. In 2012, approximately 23,300 Canadians were diagnosed with CRC and 9,200 have succumbed to the disease. A major challenge in improving treatment response in CRC patients is the development of chemotherapy resistance in tumors. In particular, resistance is thought to be conferred by a subset of proteins that are differentially expressed in CRC. To identify novel approaches to re-sensitize CRC cells to therapy, a comprehensive understanding of how these proteins counteract drug-induced cell death is needed. My proposed research aims at delineating the role of NPM1, a protein that is highly expressed in CRC, in perturbing key signaling pathways that are important in controlling abnormal cell growth. In particular, details of how NPM1 antagonizes drug-induced cell death will be examined. This knowledge will aid in the design of novel therapies to overcome cancer chemotherapy resistance.
Department
Program
Fellowship - Priority Announcement: Gastroenterology
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
302115
Name
Yu Angel Chia-yu
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Canadian Association of Gastroenterology (Oakville, Ontario)
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
The role of NPM1 in apoptosis resistance in colorectal cancer
Programtype2
Fellowship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$45,000
Cihrequipment2
$0
Programname2
Fellowship - Priority Announcement: Gastroenterology
Keyworddelim
Cancer Biology; Chemotherapy Resistance; Gastroenterology; Molecular Biology; Programmed Cell Death; Protein Biochemistry; Tissue Culture
Abstract
Colorectal cancer (CRC) is a leading cause of cancer-related deaths in Canada. In 2012, approximately 23,300 Canadians were diagnosed with CRC and 9,200 have succumbed to the disease. A major challenge in improving treatment response in CRC patients is the development of chemotherapy resistance in tumors. In particular, resistance is thought to be conferred by a subset of proteins that are differentially expressed in CRC. To identify novel approaches to re-sensitize CRC cells to therapy, a comprehensive understanding of how these proteins counteract drug-induced cell death is needed. My proposed research aims at delineating the role of NPM1, a protein that is highly expressed in CRC, in perturbing key signaling pathways that are important in controlling abnormal cell growth. In particular, details of how NPM1 antagonizes drug-induced cell death will be examined. This knowledge will aid in the design of novel therapies to overcome cancer chemotherapy resistance.
Competitiondate
201311
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Yu, Angel Chia-yu
Approvedterm
2 ans 0 mois
Cihrcontribution2
Inst of Nutr Metabolism &Diab~ $45,000~ $0~